The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the s ...

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested —— ALKS 2680 Was Generally Well Tolerated at All Doses Tested —— Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing —DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept stu ...

Core Insights - Alkermes plc is set to present three posters related to ALKS 2680 at the SLEEP 2024 conference, highlighting its investigational oral orexin 2 receptor agonist for narcolepsy treatment [1][3] Group 1: ALKS 2680 Development - ALKS 2680 is being developed as a once-daily treatment for narcolepsy, targeting the orexin 2 receptor to improve wakefulness and control cataplexy [6][8] - The company will present data from a phase 1b study involving 10 patients with narcolepsy type 1, focusing on safety and pharmacodynamic efficacy [1][3] - The Vibrance-1 study is a phase 2 clinical trial comparing ALKS 2680 to placebo in patients with narcolepsy type 1, recently initiated following proof-of-concept data [3][7] Group 2: Patient Insights - Findings from qualitative interviews with 22 patients (12 with narcolepsy type 1 and 10 with type 2) will be presented, detailing the disease's impact on various life aspects [2][3] - The interviews aimed to uncover the burden of narcolepsy on work, mental health, daily activities, and relationships [2][3] Group 3: Presentation Details - The presentations at SLEEP 2024 include specific poster sessions on the safety and pharmacodynamic effects of ALKS 2680, study design for Vibrance-1, and patient perspectives on living with narcolepsy [4][5]

As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resurgence. Breakthroughs in personalized medicine and gene editing technologies are driving biotech forward.The global biotechnology market was valued at $1.0 trillion in 2022 and is projected to reach $3.6 trillion by 2032. Increasing demand for personalized medicine and advancements in genetic engineering will d ...

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had reported adjusted earnings of 18 per share in the year-ago quarter.ALKS’ revenues of $350.4 million rose 21.8% from the year-ago quarter’s level owing to the strong performance of its proprietary products portfolio. The top line, however, missed the Zacks Consensus Estimate of $360 million.Quarter in DetailAlkermes deri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other jurisdiction of incorporation or o ...

Alkermes plc (NASDAQ:ALKS) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief Commercial Officer Richard Pops - Chief Executive Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Umer Raffat - Evercore ISI Jason Gerberry - Bank of America Uy Ear - Mizuho Securities Jessica ...

Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.The reported revenue represents a surprise of -2.75% over the Zacks Consensus Estimate of $360.26 million. With the consensus EPS estimate being $0.59, the EPS surprise was -25.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

Financial Performance - Q1 2024 - Total revenue increased to $350.4 million, a 22% increase compared to $287.6 million in Q1 2023[10] - Proprietary net sales reached $233.5 million, a 9% increase from $214.7 million in Q1 2023[10] - LYBALVI® net sales increased significantly by 50%, reaching $57.0 million compared to $38.0 million in Q1 2023[10] - VIVITROL® net sales saw a slight increase of 1%, reaching $97.7 million compared to $96.7 million in Q1 2023[10] - ARISTADA® net sales decreased by 2%, totaling $78.9 million compared to $80.1 million in Q1 2023[10] - Manufacturing and royalty revenue increased by 60% to $116.8 million, up from $72.9 million in Q1 2023[10] Financial Expectations - 2024 - The company anticipates total revenues between $1.5 billion and $1.6 billion for the year ending December 31, 2024[12] - The company projects GAAP net income between $350 million and $390 million and EBITDA between $445 million and $485 million[12] - Non-GAAP net income is expected to be between $465 million and $505 million[12] Product Sales Outlook - 2024 - VIVITROL® net sales are projected to be between $410 million and $430 million[13] - ARISTADA® net sales are expected to range from $340 million to $360 million[13] - LYBALVI® net sales are projected to be between $275 million and $295 million[13]

Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.42%. A quarter ago, it was expected that this drugmaker would post earnings of $0.46 per share when it actually produced earnings of $0.48, delivering a surprise of 4.35%.Over the last four quarters, the company has s ...